Image by: iStock
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
In an exclusive interview with Benzinga on Monday, Kelsey Ramsden, the CEO of Mind Cure Health Inc. MCURF, shared insight into Mind Cure’s press release on Nov. 4, 2021, and shed light on the potential the company is looking to unlock.
Research into MDMA treatments for psychological illnesses is meeting with official acceptance as public firms enter the space. Enveric Biosciences Inc. ENVB recently bought MagicMed, a biotechnology company focused on creating a library of novel derivative molecules based on classic psychedelics. COMPASS Pathways Plc CMPS is a British mental health care company researching how psilocybin therapy could help people with treatment-resistant depression.
Speaking to the completed draft research protocol for the use of MDMA and psychotherapy, which are used to treat female sexual hypoactive desire disorder, Ramsden said “We have the protocol completed, and soon you’ll see us, as shown in our catalysts, applying for a pre-IND meeting with the FDA, and then as we understand it we’ll be heading into a phase-2 study.”
Additionally, in March 2021, Mind Cure broke the news it was initiating chemical synthesis routes for fully synthetic ibogaine production. According to Ramsden, ibogaine, a naturally occurring psychoactive substance found in plants, is known for its effect on opiate withdrawal and opiate recovery. Speaking specifically to the updates on ibogaine production, Ramsden said “We’re the first, that we know of, that has a full synthetic ibogaine program, so driving that into some animal models and advancing that research, we should have product on the market in Q2 that would be available for researchers as well, so not only doing our own research, but also selling drug products to others.”
Mind Cure’s digital platform update also came into focus during the interview, with Ramsden sharing information about potential and future accomplishments made possible after its recent discoveries. According to the press release from Mind Cure, the company released the MVP of its digital therapeutics technology, iSTRYM, into partner clinics throughout North America in August. The release also references Mind Cure’s plan to commence full commercial deployment to all its partner clinics early in 2022, with plans for expansion into the U.K. and Europe by the later half of Q4 in 2022.
Two new novel programs from Mind Cure were also a point of consideration during the interview, and Ramsden provided context about development of the intellectual property (IP) that it feels has indications of merit. MC-106 and MC-808 are both candidate selection programs currently underway according to the press release, and although the overall information provided was semi limited, Ramsden did comment on updates being available in the second quarter of 2022, painting the picture for potential announcements.
Ramsden rounded out the interview by commenting on Mind Cure’s future progress, saying: “Because of the number of programs we have ongoing, we have a fairly robust catalyst list coming over the next eight to ten months, on both sides of the program with the technology side and on the drug development side.”
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.